Synthetic-Biology Startup Antheia Raises $73 Million

Antheia Inc., a startup using synthetic biology to produce medicines currently sourced from plants, has raised $73 million in new venture-capital financing…
Antheia Announces $73M Series B to Commercialize Synthetic Biology Platform for Essential Medicines

Led by Viking Global Investors, the Series B round will be used to bring Antheia’s first pharmaceutical compounds to market, expand its pipeline and scale production in global markets…
Synthetic biology firm Antheia collects $73m Series B

Menlo Park, California-based Antheia, a synthetic biology company, has raised $73 million in Series B financing. Viking Global Investors led the round with participation from other investors that included Sherpalo Ventures and Hillspire…
Antheia Inks $73M Series B Financing Round

Antheia, a synthetic biology company enabling next-generation plant-inspired medicines, has raised $73 million in Series B financing.
Antheia nabs $73M for synthetic biology platform

Antheia has raised $73 million to support the commercialization of its first pharmaceutical compound and the scale-up of production of active pharmaceutical ingredients and key starting materials on its synthetic biology platform…
Antheia at SynBioBeta 2020

Earlier this month, my cofounder Kristy Hawkins and I presented at SynBioBeta 2020, the flagship conference for the synthetic biology community. This year’s virtual event brought together academics, industry veterans…